Stock Price & Analysis

Based on the recent price action and technical indicators, NTRA stock shows a bullish momentum with the stock closing at $70.01 on February 16th, near its recent highs. The stock has strong institutional backing with Druckenmiller's Duquesne Family Office maintaining it as their largest holding, suggesting continued confidence in the company's prospects.

Based on the provided data and recent market trends, here's the price prediction for NTRA stock in 2025:

NTRA's stock price is expected to reach $195-205 by end of 2025, driven by strong revenue growth and margin improvements. The company's recent insider transactions show CFO selling activities, but institutional investors remain balanced with 246 adding and 256 decreasing positions, suggesting stable institutional confidence.

Technical analysis indicates a strong upward trend with current price at $176, already above all major moving averages (SMA 200 at $131.26 and SMA 50 at $167.91). The Fibonacci resistance levels show next targets at $178.01 (R1) and $181.41 (R2), supporting the bullish outlook.

The S1 support level for NTRA Stock is $161.88 ,The R1 resistant level for NTRA Stock is $178.08.

As of the end of day on 2025-02-21, the price of NTRA Stock was $161.79.

The target price for NTRA Stock according to analyst rating is 193.08, with the highest price target at 209.00 and the lowest at 175.00. Analysts have a Strong Buy rating on NTRA Stock overall.

The market cap of NTRA is $21.4B.

Based on the technical indicators and recent market data, NTRA appears to be trading at elevated levels but not significantly overvalued. The stock is currently trading at $176, showing strong momentum with a 14-day RSI of 54.16 indicating balanced buying pressure. Recent insider selling activity from executives suggests some internal skepticism about current valuations, though this could be routine profit-taking. The stock remains Duquesne Family Office's largest holding, indicating institutional confidence in the company's long-term prospects. Technical analysis shows the stock trading above all major moving averages (5,10,20,60,200-day SMAs), suggesting a healthy uptrend despite being near the upper Bollinger Band range.

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Based on the provided data and market analysis, here is the price prediction for NTRA stock by 2030:

NTRA stock is projected to reach $350-375 by 2030, driven by strong genetic testing market growth and the company's leading position in non-invasive prenatal testing. The stock has shown robust technical momentum with a 52-week range of $60-176 and maintains positive institutional sentiment as evidenced by Druckenmiller's Duquesne Family Office maintaining NTRA as their largest holding. The company's expanding product portfolio and improving operational metrics support this long-term bullish outlook.

NTRA has a total of 3282 employees.